Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Grant MD

Michael J. Grant MD

Assistant Professor of Medicine, Section of Medical Oncology, Yale University School of Medicine; Medical Oncologist and Hematologist, Yale Cancer Center/ Smilow Waterbury Care Center, New Haven, Connecticut

Dr. Michael Grant is an Assistant Professor of Medicine in the Section of Medical Oncology at Yale University School of Medicine.  He is a practicing Medical Oncologist and Hematologist at Yale Cancer Center/ Smilow Waterbury Care Center with a clinical focus on thoracic and genitourinary malignancies.  Dr. Grant’s current research interests include clinical trials and translational work aimed at understanding the biology of lung cancer, including oncogene-driven non-small cell lung cancer.  Dr. Grant has received an ASCO- Conquer Cancer Foundation Young Investigator Award as well and has completed the Yale Cancer Center T32 Advanced Training Program for Physician Scientists. 

Dr. Grant obtained his undergraduate degree with a dual major in Mathematics and Biology from Dickinson College in Carlisle, Pennsylvania.  He then graduated from the Albert Einstein School of Medicine, where he obtained his MD.  Dr. Grant then completed residency training in Internal Medicine at Duke University Hospital, Duke University School of Medicine where he was awarded the Robert M. Califf, MD Medicine Resident Research Award.

Recent Contributions to PracticeUpdate:

  1. First-Line Therapy for Metastatic Squamous Lung Cancer With PD-L1 0%
  2. ALK-Rearranged Oligometastatic NSCLC
  3. A 76-Year-Old Man With COPD and Metastatic Lung Adenocarcinoma
  4. Advanced NSCLC: Anti-PD-1 Rechallenge After Immune-Related Toxicity
  5. Stage IIIB Lung Adenocarcinoma With EGFR L858R Mutation
  6. Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Introduction
  7. Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Sotorasib
  8. Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Amivantamab
  9. Optimal First-Line Precision Therapy for Adenocarcinoma

Most Read This Week

Recently Updated